Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques

Retrovirology

Volumn 3, Issue , 2006, Pages

  Metzner, Karin J ^a,e   Binley, James M ^b   Gettie, Agegnehu ^c   Marx, Preston ^c   Nixon, Douglas F ^d   Connor, Ruth I ^a,f  

^a ROCKEFELLER UNIVERSITY   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; PROTEIN P27; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TENOFOVIR; VIRUS ANTIBODY; VIRUS RNA;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL LOSS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; FOLLOW UP; NONHUMAN; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; RNA ANALYSIS; SENSITIVITY ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS DETECTION; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ADENINE; ANIMALS; ANTI-HIV AGENTS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DRUG RESISTANCE, VIRAL; MACACA MULATTA; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33846659800     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-3-97     Document Type: Article

References (43)

1. Egger M Hirschel B Francioli P Sudre P Wirz M Flepp M Rickenbach M Malinverni R Vernazza P Battegay M Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study BMJ 1997 315 1194-1199 9393221
2. Palella FJ Jr Delaney KM Moorman AC Loveless MO Fuhrer J Satten GA Aschman DJ Holmberg SD Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 1998 338 853-860 10.1056/ NEJM199803263381301 9516219
3. Sterne JA Hernan MA Ledergerber B Tilling K Weber R Sendi P Rickenbach M Robins JM Egger M Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study Lancet 2005 366 378-384 10.1016/S0140-6736(05)67022-5 16054937
4. Phillips AN Dunn D Sabin C Pozniak A Matthias R Geretti AM Clarke J Churchill D Williams I Hill T Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice AIDS 2005 19 487-494 10.1097/ 01.aids.0000171414.99409.fb 15764854
5. Barbour JD Grant RM The Role of Viral Fitness in HIV Pathogenesis Curr HIV/AIDS Rep 2005 2 29-34 16091246
6. Buckheit RW Jr Understanding HIV resistance, fitness, replication capacity and compensation: Targeting viral fitness as a therapeutic strategy Expert Opin Investig Drugs 2004 13 933-958 10.1517/ 13543784.13.8.933 15268633
7. Shet A Markowitz M Transmitted multidrug resistant HIV-1: New and investigational therapeutic approaches Curr Opin Investig Drugs 2006 7 709-720 16955682
8. Turner D Wainberg MA HIV transmission and primary drug resistance AIDS Rev 2006 8 17-23 16736948
9. Mason RD Bowmer MI Howley CM Gallant M Myers JC Grant MD Antiretroviral Drug Resistance Mutations Sustain or Enhance CTL Recognition of Common HIV-1 Pol Epitopes J Immunol 2004 172 7212-7219 15153547
10. Stratov I Dale CJ Chea S McCluskey J Kent SJ Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1 J Virol 2005 79 7728-7737 1143690 15919925 10.1128/JVI.79.12.7728-7737.2005
11. Shehu-Xhilaga M Tachedjian G Crowe SM Kedzierska K Antiretroviral compounds: Mechanisms underlying failure of HAART to eradicate HIV-1 Curr Med Chem 2005 12 1705-1719 10.2174/0929867054367211 16029143
12. Van Rompay KK Antiretroviral drug studies in nonhuman primates: A valid animal model for innovative drug efficacy and pathogenesis experiments AIDS Rev 2005 7 67-83 16092501
13. Taber R Rajakumar PA Fuller DH Trichel AM Dowling P Meleason D Amedee A Murphey-Corb M Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate Virology 2006 354 116-131 10.1016/j.virol.2006.06.025 16884757
14. Van Rompay KKA Singh RP Pahar B Sodora DL Wingfield C Lawson JR Marthas ML Bischofberger N CD8+-Cell-Mediated Suppression of Virulent Simian Immunodeficiency Virus during Tenofovir Treatment J Virol 2004 78 5324-5337 400346 15113912 10.1128/JVI.78.10.5324-5337.2004
15. Koff WC Johnson PR Watkins DI Burton DR Lifson JD Hasenkrug KJ McDermott AB Schultz A Zamb TJ Boyle R HIV vaccine design: Insights from live attenuated SIV vaccines Nat Immunol 2006 7 19-23 10.1038/ni1296 16357854
16. Connor RI Montefiori DC Binley JM Moore JP Bonhoeffer S Gettie A Fenamore EA Sheridan KE Ho DD Dailey PJ Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine J Virol 1998 72 7501-7509 109989 9696847
17. Metzner KJ Jin X Lee FV Gettie A Bauer DE Di Mascio M Perelson AS Marx PA Ho DD Kostrikis LG Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine J Exp Med 2000 191 1921 1931 10.1084/jem.191.11.1921 10839807
18. Baba TW Jeong YS Pennick D Bronson R Greene MF Ruprecht RM Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques Science 1995 267 1820 1825 10.1126/science.7892606 7892606
19. Baba TW Liska V Khimani AH Ray NB Dailey PJ Penninck D Bronson R Greene MF McClure HM Martin LN Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques Nat Med 1999 5 194-203 10.1038/8859 9930868
20. Van Rompay KK Cherrington JM Marthas ML Berardi CJ Mulato AS Spinner A Tarara RP Canfield DR Telm S Bischofberger N 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques Antimicrob Agents Chemother 1996 40 2586-2591 163581 8913470
21. Tsai CC Follis KE Sabo A Beck TW Grant RF Bischofberger N Benveniste RE Black R Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine Science 1995 270 1197-1199 10.1126/science.270.5239.1197 7502044
22. Van Rompay KK Berardi CJ Aguirre NL Bischofberger N Lietman PS Pedersen NC Marthas ML Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection AIDS 1998 12 F79-F83 9662190
23. Tsai CC Follis KE Beck TW Sabo A Bischofberger N Dailey PJ Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques AIDS Res Hum Retroviruses 1997 13 707-712 9168239
24. Regier DA Desrosiers RC The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus AIDS Res Hum Retroviruses 1990 6 1221-1231 2078405
25. Larsson M Jin X Ramratnam B Ogg GS Engelmayer J Demoitie MA McMichael AJ Cox WI Steinman RM Nixon D A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals AIDS 1999 13 767-777 10.1097/ 00002030-199905070-00005 10357375
26. Hodge S de Rosayro J Glenn A Ojukwu IC Dewhurst S McClure HM Bischofberger N Anderson DC Klumpp SA Novembre FJ Postinoculation PMPA treatment, but not preinoculation immunomodulatory therapy, protects against development of acute disease induced by the unique simian immunodeficiency virus SIVsmmPBj J Virol 1999 73 8630-8639 112883 10482616
27. Lifson JD Piatak M Jr Cline AN Rossio JL Purcell J Pandrea I Bischofberger N Blanchard J Veazey RS Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge J Med Primatol 2003 32 201-210 10.1034/j.1600-0684.2003.00026.x 14498980
28. Rosenwirth B ten Haaft P Bogers WM Nieuwenhuis IG Niphuis H Kuhn EM Bischofberger N Heeney JL Uberla K Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques J Virol 2000 74 1704-1711 111645 10644340 10.1128/JVI.74.4.1704-1711.2000
29. Silvera P Racz P Racz K Bischofberger N Crabbs C Yalley-Ogunro J Greenhouse J Jiang JB Lewis MG Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques AIDS Res Hum Retroviruses 2000 16 791-800 10.1089/088922200308783 10826485
30. Tarantal AF Marthas ML Shaw JP Cundy K Bischofberger N Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): Safety and efficacy studies J Acquir Immune Defic Syndr Hum Retrovirol 1999 20 323-333 10096575
31. Van Rompay KK Dailey PJ Tarara RP Canfield DR Aguirre NL Cherrington JM Lamy PD Bischofberger N Pedersen NC Marthas ML Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques J Virol 1999 73 2947-2955 104054 10074144
32. Van Rompay KK Singh RP Brignolo LL Lawson JR Schmidt KA Pahar B Canfield DR Tarara RP Sodora DL Bischofberger N The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters J Acquir Immune Defic Syndr 2004 36 900-914 15220696
33. Jin X Bauer DE Tuttleton SE Lewin S Gettie A Blanchard J Irwin CE Safrit JT Mittler J Weinberger L Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques J Exp Med 1999 189 991-998 10.1084/jem.189.6.991 10075982
34. Schmitz JE Kuroda MJ Santra S Sasseville VG Simon MA Lifton MA Racz P Tenner-Racz K Dalesandro M Scallon BJ Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes Science 1999 283 857-860 10.1126/science.283.5403.857 9933172
35. Metzner KJ Moretto WJ Donahoe SM Jin X Gettie A Montefiori DC Marx PA Binley JM Nixon DF Connor RI Evaluation of CD8+ T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus J Gen Virol 2005 86 3375-3384 10.1099/vir.0.81206-0 16298985
36. Hofmann-Lehmann R Vlasak J Williams AL Chenine AL McClure HM Anderson DC O'Neil S Ruprecht RM Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation AIDS 2003 17 157-166 10.1097/00002030-200301240-00004 12545074
37. Zidek Z Holy A Frankova D Antiretroviral agent (R)-9-(2-phosphonomethoxypropyl)adenine stimulates cytokine and nitric oxide production Eur J Pharmacol 1997 331 245-252 10.1016/ S0014-2999(97)01004-2 9274986
38. Zidek Z Frankova D Holy A Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1beta) production Antimicrob Agents Chemother 2001 45 3381-3386 90841 11709312 10.1128/AAC.45.12.3381-3386.2001
39. Kedzierska K Crowe SM Cytokines and HIV-1: Interactions and clinical implications Antivir Chem Chemother 2001 12 133-150 12959322
40. Van Rompay KK Cherrington JM Marthas ML Lamy PD Dailey PJ Canfield DR Tarara RP Bischofberger N Pedersen NC 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA Antimicrob Agents Chemother 1999 43 802-812 89210 10103184
41. Schmitt M Harrer E Goldwich A Bauerle M Graedner I Kalden JR Harrer T Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes AIDS 2000 14 653-658 10.1097/00002030-200004140-00004 10807188
42. Nixon DF Donahoe SM Kakimoto WM Samuel RV Metzner KJ Gettie A Hanke T Marx PA Connor RI Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine Virology 2000 266 203-210 10.1006/viro.1999.0078 10612675
43. Moretto WJ Drohan LA Nixon DF Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry AIDS 2000 14 2625-2627 10.1097/00002030-200011100-00034 11101083